Lyra Therapeutics, Inc.
DelistedCIK 1327273fmd_1GEMW5TRVCQESDQ143S5GFWSAXManufacturing · Surgical & Medical Instruments & ApparatusTemplate: Standard
Coverage: Jan 01, 2019 to Dec 31, 2025, 28 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 0 | 1 | 2 | 2 | 0 |
| Research and development | 12 | 13 | 30 | 39 | 48 | 44 | 18 |
| Total operating expenses | 17 | 22 | 44 | 58 | 69 | 98 | 31 |
| Operating income | (17) | (22) | (44) | (56) | (67) | (96) | (31) |
| Interest and investment income | 0 | 0 | 0 | 1 | 4 | 3 | 1 |
| Other non-operating income (expense) | 0 | 0 | 0 | 1 | 4 | 3 | 2 |
| Income before taxes | – | – | (44) | (55) | (63) | (93) | (29) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | (44) | (55) | (63) | (93) | (29) |
| Net income | (16) | (22) | (44) | (55) | (63) | (93) | (29) |
| Net income to common shareholders | (17) | (22) | (44) | (55) | (63) | (93) | (29) |